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Oxidation therapy: the use of a reactive oxygen species-generating
enzyme system for tumour treatment
0. Ben-Yoseph & B.D. Ross
Departments ofRadiology and Biological Chemistry, University ofMichigan, Kresge III Research Building, Room R3315, Ann
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Summary Oxygen radicals induce cytotoxicity via a variety of mechanisms, including DNA damage, lipid
peroxidation and protein oxidation. Here, we explore the use of a polyethylene glycol (PEG)-stabilised enzyme
capable of producing reactive oxygen species (ROS), glucose oxidase (GO), for the purpose of harnessing the
cytotoxic potential of ROS for treating solid tumours. PEG-GO (200 U), administered by two intratumoral
injections 3 h apart, produced a significant growth delay in subcutaneous rat 9L gliomas as compared with
control animals receiving heat-denatured PEG-GO. Rats were protected from systemic toxicity by subsequent
i.v. administration of PEG-superoxide dismutase (PEG-SOD) and PEG-catalase. In vivo tumour metabolic
changes, monitored using 31P magnetic resonance spectroscopy (3'P-MRS) 6 h following initial administration
of PEG-GO, revealed a 96 ± 2% reduction in the ATP/P, ratio and a 0.72 ± 0.10 unit decline in intracellular
pH. A 3-fold sensitisation of 9L glioma cells in vitro to hydrogen peroxide could be achieved by a 24 h
preincubation with buthionine sulphoximine (BSO). This study suggests that oxidation therapy, the use of an
intratumoral ROS-generating enzyme system for the treatment of solid tumours, is a promising area which
warrants further exploration.
Hydrogen peroxide is produced in mammalian cells during
normal metabolism by different oxidases and from either
spontaneous or superoxide dismutase (SOD)-catalysed
superoxide anion dismutation. Hydrogen peroxide can
readily cross cellular membranes, and the most sensitive cel-
lular target structure for hydrogen peroxide is DNA, in
which single-strand breaks occur (Hoffman & Meneghini,
1979; Bradley & Erickson, 1981; Imlay et al., 1988). This
genotoxicity has been proposed to be the result of transition
metal-driven Haber-Weiss reactions leading to the genera-
tion of cytotoxic hydroxyl radicals (Filho & Meneghini,
1984). Over the past 40 years there have been many attempts
to treat tumour-bearing patients or animals with preformed
hydrogen peroxide (Hollcroft et al., 1952; Makino & Tanaka,
1953; Turner, 1953; Green & Westrop, 1958; Sugiura, 1958;
Krementz et al., 1963; Mealey, 1965; Kaibara et al., 1971). In
these reports, hydrogen peroxide was injected directly into
the solid tumour, the circulation or the peritoneal cavity of
mice with malignant ascites. The results from these studies,
however, were anecdotal. It was not until the early 1980s that
investigators reported that hydrogen peroxide can exert a
direct anti-tumour effect in vivo and thus prolong host sur-
vival (Nathan & Cohn, 1981). In that previous study, glucose
oxidase (EC 1.1.3.4) was conjugated to carboxylated latex
micropheres and was found to have an anti-tumour effect
both in the peritoneal cavity and when injected into the
tumour bed of subcutaneously implanted P388 cells at the
time of cell implantation (Nathan & Cohn, 1981). The micro-
spheres were at the tumour site and hydrogen peroxide
generation was achieved through the following reaction:
GO
P-D-Glucose + 02------------> D-glucono-1,5-lactone + H202
It is known that enzymes can be stabilised in vivo by
attaching PEG units to the lysine residues. Enzyme
modification in this manner increases in vivo half-life from
6 min to 30-40 h, reduces the antigenicity of the native
protein and inhibits proteolysis (Pyatak et al., 1980). To our
knowledge, there have been no reports demonstrating growth
inhibition of a solid tumour using hydrogen peroxide or a
hydrogen peroxide-generating system. The unrealised poten-
tial of this treatment was the motivating factor for this
present study, in which we describe the anti-tumour effect of
PEG-GO on the growth of cultured 9L glioma cells and
solid s.c. 9L tumours in rats. In addition, results using 31P-
MRS to examine the effects of this therapeutic approach on
tumour phosphate metabolites and pH in vivo are presented.
Materials and methods
Preparation ofPEG-glucose oxidase (PEG-GO)
The preparation of PEG-catalase, PEG-SOD and
PEG-GO was accomplished using previously reported pro-
cedures for PEG-SOD (Pyatak et al., 1980). In brief,
PEG-GO was prepared by addition of 40mg of protein
(Aspergillus niger) in 10 ml of 0.1 M boric acid, pH 9.8.
Activated PEG (1.0 g; Mr 5,000, Sigma, St Louis, MO, USA)
was added and the mixture was stirred for 1 h. Unattached
PEG was removed by five sequential dialysis steps against
equivalent volumes of phosphate-buffered saline (PBS) (cal-
cium chloride, 0.9 mM; potassium chloride 2.7 mM; potassium
dihydrogen phosphate 1.5 mM; magnesium chloride 0.3 mM;
sodium chloride 137.0 mM; disodium hydrogen phosphate,
7.5 mM) using an Amicon (Beverly, MA, USA) ultrafiltration
chamber (model 8050) equipped with an XM-50 membrane.
The Mr and activity of PEG-GO were determined by laser
desorption linear time-of-flight mass spectrometry (Vestec
Model VT 2000) and spectrophotometry (Michiels &
Remacle, 1988) respectively. PEG-SOD and PEG-catalase
were assayed for activity using standard spectrophotometric
methods (Pyatak et al., 1980; Michiels & Remacle, 1988).
Sulforhodamine B (SRB) cell toxicity assay
Rat 9L glioma cells were grown until confluent as
monolayers in 75 cm2 sterile plastic flasks in modified Eagles
minimum essential medium containing 10% fetal calf serum
at 37°C in a humidified atmosphere containing 95% air and
5% carbon dioxide. Cells were harvested by trypsinisation,
counted, diluted in serum-free medium, plated in 96-well
culture plates at a density of 1,000 cells per well and allowed
to grow for 24 h before treatment. Increasing concentrations
of PEG-GO and hydrogen peroxide were subsequently
added to the 9L cells in Krebs-Ringer bicarbonate buffer
(KRB) sodium chloride 113.0 mM; sodium bicarbonate
29.0 mM; potassium chloride 4.6 mM; magnesium sulphate
0.5 mM; disodium hydrogen phosphate 0.6 mM; potassium
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hydrogen phosphate 0.3 mM; potassium bicarbonate 1.0 mM;
calcium chloride 2.5 mM; glucose, 5.5 mM; pH = 7.4) for a 60
and 30 min exposure period respectively. The activity of
PEG-GO was determined in KRB on the same day of cell
exposures to ensure accurate dosing. An automated microcul-
ture assay using SRB (a protein-binding dye; Rubinstein et
al., 1990) was used to quantitate the toxicity of preformed
and PEG-GO-generated hydrogen peroxide on cultured 9L
glioma cells. Under the conditions used in this study, the
optical absorbance was directly proportional to the number
of 9L cells. Following hydrogen peroxide exposure, cells were
gently rinsed three times and allowed to grow for 4 days. The
cells were then fixed and stained, and the absorbance values
were obtained using an AutoReader microtitre plate reader
(Cayman Chemicals, Ann Arbor, MI, USA). Toxicity was
assessed in terms of fractional cell survival relative to control.
Studies to evaluate the effects of reduced intracellular
glutathione (GSH) levels on sensitivity of 9L tumour cells
were done by preincubating cells for 24 h in the presence of
0.1, 0.5, 1, 2 and 5 mM buthionine sulphoximine (BSO)
before exposure to increasing concentrations of hydrogen
peroxide as described above. GSH levels were determined
spectrophotometrically using a kit provided by Bioxytech
(Marne, France).
In vivo evaluation ofPEG-GO
Specific pathogen-free male Fischer-344 rats were purchased
from Charles River Breeding Laboratories (Wilmington, MA,
USA). Rats weighed 275-300 g at the beginning of the
experiment and were housed in the university laboratory
animal medicine facility. All procedures were approved by
the Institutional Animal Care and Use Committee. Sub-
cutaneous gliomas were induced by injection of 1 x 106 9L
glioma cells in 0.2 ml of serum-free culture medium over the
right thigh muscle under halothane anaesthesia. Calliper
measurements of tumour dimensions were repeated every 2
days beginning on the eighth day post cell implantation.
Tumour volumes were determined using the equation:
Tumour volume = 0.5 (length x width2). Rats with sub-
cutaneous gliomas were treated 12 days after cell inoculation,
at which time the mean tumour volume was approximately
0.7 cm3. PEG-GO (50 or 200 U) contained in 50 lAl of
phosphate-buffered saline (PBS) was administered by an
intratumoral injection. Tumours treated with 200 U of
PEG-GO received a second identical injection 3 h later.
Care was taken to distribute the PEG-GO as evenly as
possible throughout the tumour mass. At the conclusion of
the second 200 U PEG-GO injection, 10,000 U each of
PEG-SOD and PEG-catalase were administered i.v. in
order to protect the animals from systemic toxicity owing to
the potential leakage of hydrogen peroxide and/or the
PEG-GO from the tumour site into the vascular system.
Control animals were treated identically except that the
PEG-GO was denatured by heating at 90°C for 15 min prior
to injection.
In order to determine the effects of this therapy on cellular
energy state in vivo, 3'P-MR spectra were recorded on several
animals before and 6 and 24h after intratumoral injection
using a horizontal-bore 7T Spectroscopy Imaging Systems
magnetic resonance instrument. For MRS experiments, rats
were anaesthetised by an i.p. injection of a mixture contain-
ing ketamine (80-100mgkg-') and xylazine (13mgkg-').
3TP-MR spectra were recorded using a single-turn 9-mm
diameter surface coil probe at 121.4 MHz using the following
acquisition parameters: sweep width = ± 3,000 Hz; number
of transients = 1,000; interpulse delay = 2.3 s; number of data
points = 4096. 3"P-MR spectra were apodised with a 30 Hz
exponential line-broadening function prior to Fourier trans-
formation. Quantification of ATP and inorganic phosphate
(Pi) resonance areas was accomplished using a spectral
deconvolution routine and pH was calculated from the
chemical shift of Pi relative to phosphocreatine (PCr). When
the PCr resonance was absent, the water resonance from the
proton spectra obtained during shimming procedures was
used to calculate the position of PCr and hence pH as
previously described (Madden et al., 1991). Determination of
pH values using this approach has been reported to be well
within the expected accuracy of the NMR pH measurement
of ± 0.05-0.1 pH units (Roberts et al., 1981).
Statistical analysis
Piecewise linear regression (Wasserman & Kutner, 1990) was
used to model growth in tumour volume as a function of
time, allowing for a different rate of growth in the treated
group following treatment on day 12. The natural logarithm
of tumour volume was used as the dependent variable
because preliminary analysis indicated that the tumour
volume increases in an approximately exponential manner
with increasing time. The independent variables in the model
were time in days since implantation and, for the treated
group, time since treatment began. This variable was equal to
zero both for the control group and for the treated group
before treatment.
For 31P-MR data, all values are reported as means ± s.e.
Results
Characterisation ofPEG-GO
The average Mr of native GO and PEG-GO was determined
to be 150 and 185 kDa respectively. Because the PEG used in
this study had a Mr of 5,000, an average of seven PEG
moieties were attached to each PEG-GO molecule. Attach-
ment of PEG reduced the enzymatic activity by 40% com-
pared with native glucose oxidase as estimated from
Lineweaver-Burk plots (data not shown).
In vitro cytotoxicity studies
Survival studies of 9L glioma cells 4 days following exposure
to increasing activities of PEG-GO for 60 min revealed that
this enzyme system is cytotoxic to 9L glioma cells (Figure
la). Cytotoxicity studies of 9L glioma cells following a
30 min exposure to preformed hydrogen peroxide revealed a
dose-dependent toxicity with an IC50 = 60pM (n = 16, Figure
lb). In the presence of 0.1 mM BSO, an inhibitor of GSH
synthesis, the IC50 decreased to 22ILM hydrogen peroxide,
indicating an approximate 3-fold increased sensitivity to hyd-
rogen peroxide (Figure lb). Cell toxicity following a 24 h
incubation with 0.5, 1, 2 and 5 mM BSO was identical to that
observed for 0.1 mM BSO. Spectrophotometric determination
of intracellular GSH levels under these conditions revealed a
decreae from 42 to 20 nmol mg-' protein with 0.1 mM BSO.
At BSO concentrations of 0.5 mM or higher, GSH was not
detectable.
In vivo 3"P-MRS andgrowth inhibitor studies
Shown in Figure 2 are in vivo 3'P-MR spectra of a sub-
cutaneous 9L glioma acquired before PEG-GO injection
(Figure 2a) and 6 h (Figure 2b) and 24 h (Figure 2c) follow-
ing intratumoral injection of 50 U of PEG-GO. The spect-
rum obtained 6 h post intratumoral injection of 50 U
PEG-GO shows a significant impairment of the energy state
as indicated by the decrease in the PCr and ATP resonances
and the increase in Pi. However, after 24 h, the energy state
almost completely recovered and the rate of tumour growth
remained unretarded. Shown in Figure 3 are representative in
vivo 3'P-MR spectra of subcutaneous 9L gliomas acquired
before tumour treatment (Figure 3a) and 6 h following int-
ratumoral injection of 2 x 200 U of denatured PEG-GO
(Figure 3b) and active (2 x 200 U) PEG-GO (Figure 3c).
Intratumoral injection of heat-denatured PEG-GO (Figure
3b) resulted in a 34 ± 17% (n = 3) decline in tumour ATP/Pi
levels and a reduction in tumour pH by 0.10 ± 0.10 U
(n = 3). Administration of active PEG-GO resulted in the
nearly complete loss of PCr and ATP and a reciprocal in-
crease in Pi (Figure 3c). For PEG-GO-treated animals, theTREATMENT OF TUMOURS WITH A HYDROGEN PEROXIDE GENERATING SYSTEM 1133
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Figure 1 Effect of preformed and PEG-GO-generated hydrogen
peroxide on 9L glioma cell growth in vitro. a, 9L glioma cells
were incubated for 1 h with increasing activity of PEG-GO and
allowed to grow for 4 days (n = 8 s.e.). b, Control (0) and
preincubated (E) (24 h with 0.1 mM BSO) 9L cells were
incubated with increasing concentrations of preformed hydrogen
peroxide for 30 min and allowed to grow for 4 days
(n = 16 s.e.). Cytotoxicity was measured using the SRB assay
and data are expressed as per cent of control cell growth.
ATP/Pi ratio decreased by 96 ± 2% (n = 3) and was accom-
panied by a 0.72 ± 0.10 (n = 3) decline in tumour pH. Shown
in Figure 4 is a plot of the average 9L subcutaneous tumour
volumes vs the number of days after cell implantation for the
control (denatured PEG-GO) and PEG-GO-treated sub-
cutaneous 9L gliomas. The difference in growth rates
between control and treated groups beginning at day 12 is
significant at P<0.001.
Tumours treated with 2 x 200 U PEG-GO turned from
pink to a dark-brown/black colour within approximately 4 h
after initiation of the treatment, accompanied by a swelling
of the tumour tissue. In contrast, no significant changes in
the appearance and size of tumours injected with denatured
PEG-GO were found. A swelling of the hind limb bearing
the tumour mass was also seen following the treatment but
disappeared 1-2 days later. Rats receiving more than app-
roximately 100 U of PEG-GO, without infusion of the
antioxidative enzymes (PEG-catalase and PEG-SOD),
exhibited significant side-effects including swelling of the hind
limb, lethargy and ultimately death.
Discussion
The significant delay in tumour growth demonstrates the
feasibility of oxidation therapy, which we define as the use of
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Figure 2 In vivo 3'P-MR spectra of subcutaneous rat 9L gliomas
obtained (a) before and (b) 6h and (c) 24 h following a direct
intratumoral injection of 50 U of PEG-GO. Resonance assign-
ments are as follows: 1, phosphomonoesters; 2, Pi 3, PCr; 4,
y-ATP and P-ADP; 5, a-ATP, a-ADP and NAD; 6, unidentified
diphosphodiester, possibly UJDP sugars; 7, P-ATP.
an intratumoral ROS-generating enzyme system for the treat-
ment of solid tumours. Previous studies using direct injec-
tions of hydrogen peroxidase into solid tumours were unsuc-
cessful (Green & Westrop, 1958). A study using glucose
oxidase conjugated to latex microspheres did not report
attempts at treating solid tumours but rather tumour cells in
the peritoneal cavity and co-injection of tumour cells with the
micropheres at the time of s.c. implantation (Nathan &
Cohn, 1981). However, modification of GO and PEG
resulted in only a 40% reduction in activity as compared
with a 90% loss of enzyme activity when conjugated to latex
microspheres (Nathan & Cohn, 1981). This reduction in
activity, when combined with the increased volume taken up
by the inert microsphere material, resulted in a net 4,000-fold
decrease in total enzyme activity per volume as compared
with the PEG-GO system. Although the latex microsphere
system has the advantage of retaining the GO at the tumour
site, the therapeutic effectiveness towards solid tumours (such
as the 9L glioma) is probably limited since the injectable
volume necessary to attain the dose used in this present study
would exceed the tumour volume.
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Figure 3 Representative in vivo 3'P-MR spectra of subcutaneous
rat 9L gliomas obtained (a) before and 6 h following a direct
intratumoral injection of 2 x 200 U of (b) heat-denatured
PEG-GO and (c) active PEG-GO. Resonance assignments are
as in Figure 2.
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Figure 4 Effect of intratumoral administration of PEG-glucose
oxidase on the growth of 9L gliomas in vivo. 9L glioma cells
(I x 106) were inoculated subcutaneously into the right flank of a
Fischer 344 rat on day 0. PEG-glucose oxidase and heat-
denatured PEG-glucose oxidase was administered intratumorally
on day 12 (noted by upward pointing arrow) at two separate
doses of 200 U 3 h apart. At the conclusion of the second
PEG-glucose oxidase dose, 10,000 U each of PEG-catalase and
PEG-SOD were administered i.v. to protect the rat from
systemic oxidative stress. The difference in growth rates beginning
at day 12 is significant at P< 0.001. Points, means ± s.e. (n
= 6
control and n = 5 treated). 0, heat denatured PEG-glucose
oxidase; 0, 2 x 200 U PEG-glucose oxidase.
In this study, 3"P-MRS was used to assess the in vivo
metabolic effect of oxidation therapy since two distinct
mechanisms by which hydrogen peroxide can deplete cellular
ATP levels are known. The first mechanism involves activa-
tion of poly(ADP-ribose) polymerase following hydrogen
peroxide-induced DNA strand breaks (Schraufstatter et al.,
1986). Activation of poly(ADP-ribose)polymerase consumes
NAD+, a process that is subsequently associated with a loss
of ATP levels (Ueda & Hayaishi, 1985; Berger et al., 1986;
Bruchelt et al., 1991). This second mechanism involves hyd-
rogen peroxide inhibition of glycolysis by the inactivation of
glyceraldehyde 3-phosphate dehydrogenase resulting in deple-
tion of ATP levels (Brodie & Reed, 1987). Our results,
obtained from in vivo 3'P-MRS evaluation of treated gliomas,
are consistent with the two mechanisms mentioned above in
which ATP depletion is directly linked to oxidative stress.
31P-MR spectra of PEG-GO-treated 9L gliomas revealed a
dramatic decline in both the ATP/Pi ratio and tumour pH as
compared with the control group at 6 h post treatment. The
exact mechanism(s) for these changes could be one or a
combination of the two aforementioned, however other pos-
sibilities, such as a decrease in tumour blood flow, cannot be
ruled out. Whatever the exact mechanism(s) for cell death, it
is important to note that metabolic changes preceded the
inhibition of tumour growth, suggesting that 31P-MRS can
provide a non-invasive means for following the progress of
the treatment by monitoring ATP levels. This capability may
be very useful during the actual treatment period by pro-
viding the feedback necessary to determine when the genera-
tion of ROS could be discontinued.
Optimisation of this therapeutic approach will require imp-
rovements in the delivery and control of the ROS-generating
enzyme system and assessment of the pathological conse-
quences. Glucose oxidase was chosen to demonstrate the
concept of oxidation therapy because it has a relatively high
specific activity, is commercially available and because the
substrates necessary for hydrogen peroxide production,
glucose and oxygen are abundant in tissue. However, this
enzyme has a fundamental disadvantage in that its activity
cannot be directly controlled, necessitating administration of
large doses of antioxidative enzymes (or antioxidants) in
order to protect the rat from systemic toxicity. This tissue
may be exacerbated in the rat because blood catalase activity
in this species is only 25% of that in the human (Lorincz et
al., 1948). This disparity between species is also reflected in
the fact that human blood foams in contact with hydrogen
peroxide, whereas this phenomenon does not occur when
hydrogen peroxide is added to rat blood. Oxygenation of rat
blood does not occur, but rather the blood turns dark-brown
owing to the formation of methaemoglobin. Methaemoglobin
formation was observed in the present studies in treated rats
that were not protected by administration of PEG-catalase
and PEG-SOD.
An alternative oxidase enzyme system in which the activity
of the hydrogen peroxide generating system could be
manipulated by substrate availability and/or direct chemical
inhibition of the enzyme would provide a significant advan-
tage over glucose oxidase. This would reduce excessive
oxidative stress on surrounding normal tissues and blood.
This capability would require that the substrate is not
endogenous to mammalian tissue or present in low enough
concentrations as not to induce significant formation of hyd-
rogen peroxide. A specific example of an enzyme with these
properties is D-amino acid oxidase (DAAO) (EC 1.4.3.3).
This enzyme catalyses the following reaction and can be
manipulated by substrate depletion or chemical inhibition:
DAAO
D-Amino acid + H20 +02 ------>2-oxo acid + NH3 + H202
Therefore, the long-term development and optimisation of
oxidation therapy will necessitate the use of an oxidase in
which the activity can be manipulated.
Selectivity of oxidation therapy for gliomas will depend on
the relative sensitivity of neurons, astrocytes and glioma cells
to hydrogen peroxide-induced toxicity. We have obtained
d6%
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preliminary in vitro results showing the IC50 of a 30 min
exposure to hydrogen peroxide for rat primary neuronal and
primary astrocytic cultures to be 98 and 585tLM respectively
(0. Ben-Yoseph, P. Boxer & B.D. Ross, unpublished results),
as compared with 60fM for cultured 9L cells. We have also
shown in this present study that sensitivity to hydrogen perox-
ide could be greatly increased (3-fold) when cultured 9L
tumour cells were pretreated with BSO, (Griffith, 1982). BSO
has an additional advantage of selectivity as it has been shown
to reduce the GSH levels of intracranial gliomas without
affecting normal brain GSH levels (Lippitz et al., 1990). Thus,
pretreatment of the host with BSO should provide an excellent
method for the selective sensitisation of malignant brain
tumours to oxidation therapy. Further methods for sensitising
gliomas to oxidative stress include, for example, inhibition of
tumour antioxidant defences or DNA repair mechanisms.
Future development of oxidation therapy will entail not
only optimising the oxidase system and selective presensitisa-
tion of the tumour, but also improving methods of delivery to
the tumour site. For treatment of malignant brain tumours,
the disrupted blood-brain barrier should also allow an i.v.-
administered PEG-oxidase system selective access to the
glioma tissue. Intrathecal administration of the PEG-oxidase
substrate could provide for activation of the enzyme
predominantly within the tumour tissue. Progress of the
therapy could be monitored using localised 3'P-MRS in vivo.
There are a multitude of additional variations on how oxida-
tion therapy could be utilised for tumour treatment. Possible
delivery methods include the use of liposomes, biodegradable
polymers or attachment to monoclonal antibodies (Philpott et
al., 1980). Although the type of delivery vehicle will no doubt
vary depending upon the tumour type and host organ
targeted, our initial promising data provide evidence that
oxidation therapy is a strong candidate for tumour treatment
and warrants further evaluation.
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